Biostorage & Biospecimen Management

Biostorage is the controlled holding of biological material at a defined temperature class, with a record of where every unit is, who has touched it and what temperature it has been kept at. The material is usually blood and its fractions, urine, saliva, swabs in media, nucleic acid extracts, and the reagents and kit components that travel with them. DS2 stores specimens and kits. It does not store investigational drugs, dispensed medication or organs, and it does not broker specimens from a bank.

The reason to buy storage from the company that runs your collection kits and your courier routes is custody. A specimen that is collected in a DS2 kit, moved by a DS2 courier, stored in a DS2 freezer and shipped out by DS2 has one record from the draw to the analyzing laboratory. Split those steps across vendors and the record restarts at every handoff, which is exactly where sponsor monitors and inspectors find the gaps.

Validation studies for a new assay or device often need specimens a bank cannot supply: a defined population, a defined collection method, a matched tube set, a fresh draw within a stability window. Where that is the case, DS2's mobile phlebotomy network collects prospectively under the sponsor's IRB-approved protocol and consent, in collection kits built for the study, and the specimens move by DS2 courier into storage or straight to the testing laboratory.

The regulatory division of labor is worth stating plainly. The sponsor owns the protocol, the consent and any FDA submission. Many diagnostic device studies qualify for the IDE exemption at 21 CFR 812.2(c)(3) when the sponsor follows the investigational-use labeling in 809.10(c) and the testing is noninvasive, which the rule defines to include simple venipuncture and the use of surplus specimens, and FDA has long stated it exercises enforcement discretion on informed consent for IVD studies that use leftover specimens which are not individually identifiable. Those are the sponsor's determinations to make. DS2 executes the collection, the logistics and the storage to the specification, and keeps the custody record that the submission will rely on.

Storage does not change who is responsible for a specimen's consent; it does make the identifiability question concrete, because the provider has to know what it is holding. Under the revised Common Rule, research with identifiable biospecimens is human subjects research, and 45 CFR 46.116(d) allows broad consent for their storage, maintenance and secondary use. Research using only non-identifiable specimens generally falls outside the definition. Under HIPAA, protected health information is de-identified by the safe harbor method, removing the listed identifiers, or by expert determination, and a limited data set can support research under a data use agreement. DS2 stores material under the identifiability status the client assigns, keeps any code key separate from the specimens, and handles protected health information under a business associate agreement.

Three frameworks define good repository practice: the ISBER Best Practices for repositories, the CAP Biorepository Accreditation Program and ISO 20387 for biobanks. They are the right vocabulary for a storage agreement and the right questions for a site visit. DS2 operates storage and distribution under its ISO 13485:2016 quality system, the same system that covers kit assembly and fulfillment, with continuous monitoring, sample-level records and documented change control. One point buyers often get wrong: CLIA sets retention periods for laboratory records, not for stored specimens; the one specimen clause in 42 CFR 493.1105 is that tissue remnants are preserved until a diagnosis is made. How long a specimen is kept after testing comes from the protocol, the accreditor's checklist or the laboratory's own policy, and it should be written into the agreement.